Abstract
Over 170 years after Richard Bright and a century after Ernest H. Starling, the development, location, and severity of edema in patients with renal impairment continue to baffle the predictions of most nephrologists. While much of the phenomenon can be explained by levels of serum proteins, or hydrostatic pressures, there are stunning exceptions well known to any practicing nephrologist. Some of the derangement is undoubtedly due to unmeasured but well-known variables, such as membrane permeability; however, other factors such as free entropy of plasma are also clearly involved. The study of other polyelectrolyte colloids, similar to plasma proteins, for industrial purposes has led to the identification of various phenomena such as counterion condensation that can result in loss of entropy and consequently osmotic pressure. Variables known to result in a loss of free entropy, such as pH, oxidation products and ligand binding, are discussed. Older equations developed by van’t Hoff and Donnan might require replacement by newer mathematical models such as the nonlinear Poisson-Boltzmann equation or the Monte Carlo simulator. Attempts to restore free entropy to plasma would be a more physiological treatment of edema than diuretic use. Implications are noted for future drug development to treat edema.
References
1.
Bright R: Report of Medical Cases with a Selected View of Illustrating the Symptoms and Cure of Medical Diseases by Reference to Morbid Anatomy. London, Longman, 1827.
2.
Richet G: Edema and uremia from 1827 to 1905: The first faltering steps of renal pathophysiology. Kidney Int 1993;43:1385–1396.
3.
Starling EH: Physiologic forces involved in the causation of dropsy. Lancet 1896;i:1267–1270.
4.
Navar PD, Navar LB: Relationship between colloid osmotic pressure and plasma protein concentrations in the dog. Am J Physiol 1977;233:H295–H298.
5.
Canaan-Kuhl S, Venkatramen ES, Ernst SIB, Olshen RA, Myers BD: Relationships among proteins and albumin concentrations in nephrotic plasma. Am J Physiol 1993;264:F1052–F1059.
6.
Hammel HT: Role of colloid proteins in Starling’s hypothesis and in returning interstitial fluid to the vasa recta. Am J Physiol 1995;268:H2133–H2144.
7.
Dixon HH: Transpiration model. R Dublin Soc Proc 1903;110:114–121.
8.
Denbigh K: The principles of Chemical Equation. Cambridge, Cambridge University Press, 1981, p 262.
9.
van’t Hoff JH: Die Rolle osmotischen Drucks in der Analogie zwischen Lösungen und Gasen. Z Phys Chem 1887;1:481–508.
10.
Cameron IL, Fullerton GD: A model to explain the osmotic pressure behavior of hemoglobin and serum albumin. Biochem Cell Biol 1990;68:894–898.
11.
Donnan FG: The theory of membrane equilibria. Chem Rev 1925;1:73–91.
12.
Ilani A: On the mechanism of the osmotic phenomenon. Isr J Med Sci 1982;18:9–12.
13.
Miki K, Sagawa S, Shiraki K: Factors influencing the determination of colloid osmotic pressure in plasma. Sangyo Ika Daigaku Zasshi 1983;5:405–412.
14.
Stall G, Joslin CG: The Donnan equilibrium: A theoretical study. Biophys J 1986;50:855–859.
15.
Burton RF: The protein content of extracellular fluids and its relevance to the study of ionic regulation: Net charge and colloid osmotic pressure. Comp Biochem Physiol [A]. 1988;90:11–14.
16.
Ashbaugh HS, Paulitis ME: Entropy of hydrophobic hydration: Extension to hydrophobic chains. J Phys Chem 1996;100:1900–1913.
17.
Sturtevant J: Heat capacity and entropy changes in processes involving proteins. Proc Natl Acad Sci USA 1977;74:2236–2240.
18.
Suzuki M, Shigematsu J, Kodama T: Hydration of proteins in solution by microwave dielectric analysis. J Phys Chem 1996;100:7279–7282.
19.
Devore DI, Manning GS: Application of polyelectrolyte limiting laws to virial and asymptotic expansions for the Donnan equilibrium. Biophys Chem 1974;2:42–48.
20.
Sharp KA: Polyelectrolyte electrostatics: Salt dependence, entropic, and enthalpic contributions to free energy in nonlinear Poisson-Boltzmann model. Biopolymers 1995;36:227–243.
21.
Firestone BA, Siegel RA: pH, salt and buffer dependent swelling in ionizable copolymer gels: Tests of the ideal Donnan equilibrium theory. J Biom Sci Polym Ed 1994;5:433–450.
22.
Buschmann MD, Grodzinsky AJ: A molecular model of proteoglycan-associated electrostatic forces in cartilage mechanics. J Biomed Eng 1995;117:179–192.
23.
Will BR, Brace RA: Physiologic effects of pH changes on colloid osmotic pressure. Am J Physiol 1985;248:H890–H893.
24.
Magid AD, Kenworthy AK, McIntosh TJ: Colloid osmotic pressure of steer crystallins: Implications for origin of the refractive index gradient and transparency of the lens. Exp Eye Res 1992;55:615–627.
25.
Gulassy PF, De Torente A: Tryptophan metabolism in renal failure. Kidney Int 1975;7(suppl):311–315.
26.
Dombros N, Oren A, Marliss EB, Anderson GH, Stein AN, Khanna R, Petit J, Brandes L, Rodella H, Leibel BS, Oreopoulos D: Plasma amino acid profiles and amino acid losses in patients undergoing CAPD. Perit Dial Bull 1982;2:27–32.
27.
Pirazoli G, Casadio L, Rossini R, Guanlandi G: Correlation between tryptophan, NEFA and albumins in nephrotic syndrome. Boll Soc Ital Biol Sper 1983;59:1–7.
28.
Kovach IS: The importance of polysaccharide configurational entropy in determining the osmotic swelling of concentrated proteoglycan solution and bulk compressive modulus of articular cartilage. Biophys Chem 1995;53:181–187.
29.
Ginevri F, Ghiggeri GM, Candiano G, Oleggini R: Endogenous albumin as a marker of renal selectivity in steroid unresponsive nephrotic syndrome. Nephron 1989;52:133–138.
30.
Candiano G, Ghiggeri GM, Delfinio D, Queirolo C, Vecchio G: Isoelectric focusing in low denaturing media: Visualization in renal disease of variation of the isoelectric point of albumin not related to a remarkable conformational variation. J Chromatogr 1986;374:279–288.
31.
Min He X, Carter DC: Atomic structure and chemistry of human serum albumin. Nature 1992;358:209–214.
32.
Nikolaev V, Sarnatskaya V, von Appen K, Rotellar E, Haspar M, Klinkmann H: Biophysical studies on the correction of uremic serum albumin binding defects by in vitro charcoal adsorption treatment. Artif Organs 1996;20:17–23.
33.
Borza DB, Tatum FM, Morgan WT: Domain structure and conformation of histidine-proline rich glycoprotein. Biochemistry 1996;35:1925–1934.
34.
Meucci E, Mordente A, Martorana GE: Metal-catalyzed oxidation of human serum albumin: Conformational and functional changes. J Biol Chem 1991;266:4692–4699.
35.
Milroto M, Baksi MS, Crisantino R, Delisi R: N′N′N′-alkyloctyldimethylammonium chloride in water: A thermodynamic investigation. J Colloid Interf Sci 1993;159:354–365.
36.
Yamasaki M, Yano H, Aoki K: Differential scanning calorimetric studies on bovine serum albumin. II. Effects of neutral salts and urea. Int J Biol Macromol 1991;13:322–328.
37.
Bateman JB, Evans GF, Brown PR, Gabriel C, Grant EH: Dielectric properties of bovine albumin: Urea:betaine in aqueous solution. Phys Med Biol 1992;37:175–182.
38.
Cupisti A, Ghiggeri GM, Morelli E, Barsotti G: Fatty acid serum levels in nephrotic patients on a pure vegetarian diet. Nephron 1992;60:376–377.
39.
Joles JA, Willekes-Koolshlin N, Braam B, Kortlandt W, Koomans HA, Dorhout Mees EJ: Colloid oncotic pressure in young analbuminemic rats. Am J Physiol 1989;257:F23–F28.
40.
Celsus: De Medicina, Spencer WG (transl). Cambridge, Harvard University Press, 1938, book III, pp 180–181.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
